Oncology Venture


SEK166.3m market cap

SEK2.36 last close

Oncology Venture is a biopharmaceutical company with a patent-protected mRNA-based drug response predictor platform that identifies patients highly likely to respond to treatment. The company is entering Phase II with six in-licensed drugs.

Investment summary

Oncology Venture announced on 4 September 2019 that it has appointed a new CEO, Steve Carchedi, former senior executive of J&J and Mallinckrodt. This comes at a critical juncture for the company as it moves its programmes into the late stage and starts to look for development partners to advance these assets. The company has made substantial progress getting LiPlaCis ready to launch Phase III studies with IND and IDE applications.

Y/E Dec
Revenue (DKKm)
EPS (ore)
P/E (x)
P/CF (x)
2017A 5.1 (23.8) (31.0) (127.00) N/A N/A
2018A 2.1 (32.3) (22.5) (44.00) N/A N/A
2019E 3.6 (116.4) (117.0) (165.02) N/A N/A
2020E 3.6 (131.2) (130.3) (170.62) N/A N/A
Last updated on 16/09/2019
Industry outlook

Oncology Venture and the DRP system have the potential to identify the value in drug assets that have otherwise been discontinued by identifying patient populations where these drugs are active. This allows the company to in-license these assets at low cost, which the company may then out-license after clinical validation.

Last updated on 16/09/2019
Share price graph
Balance sheet
Forecast net debt (DKKm) 81.1
Forecast gearing ratio (%) 80
Price performance
Actual (53.9) (36.9) (76.2)
Relative* (56.8) (39.0) (76.9)
52-week high/low SEK12.7/SEK2.2
*% relative to local index
Key management
Duncan Moore Chairman
Steve Carchedi CEO
Ulla Hald Buhl Chief Operating Officer